{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:57:32Z","timestamp":1765961852188,"version":"3.28.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00520-024-08956-8","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T02:02:16Z","timestamp":1730426536000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patients\u2019 knowledge about renal secondary effects of anti-tumoral drugs and renal protection measures"],"prefix":"10.1007","volume":"32","author":[{"given":"Pauline","family":"Corbaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Bainaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Try","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnaud","family":"Saillant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Camille","family":"Lafargue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Afchain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Jamelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Isnard-Bagnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Campedel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Delaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"8956_CR1","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22904","volume":"110","author":"V Launay-Vacher","year":"2007","unstructured":"Launay-Vacher V, Oudard S, Janus N et al (2007) Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. Cancer 110:1376\u20131384. https:\/\/doi.org\/10.1002\/cncr.22904","journal-title":"Cancer"},{"key":"8956_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1093\/jnci\/djy167","volume":"111","author":"A Kitchlu","year":"2019","unstructured":"Kitchlu A, McArthur E, Amir E et al (2019) Acute kidney injury in patients receiving systemic treatment for cancer: a population-based cohort study. J Natl Cancer Inst 111:727\u2013736. https:\/\/doi.org\/10.1093\/jnci\/djy167","journal-title":"J Natl Cancer Inst"},{"key":"8956_CR3","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMra1613984","volume":"376","author":"MH Rosner","year":"2017","unstructured":"Rosner MH, Perazella MA (2017) Acute kidney injury in patients with cancer. N Engl J Med 376:1770\u20131781. https:\/\/doi.org\/10.1056\/NEJMra1613984","journal-title":"N Engl J Med"},{"key":"8956_CR4","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/ndt\/gfw338","volume":"32","author":"J Malyszko","year":"2017","unstructured":"Malyszko J, Kozlowska K, Kozlowski L, Malyszko J (2017) Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 32:924\u2013936. https:\/\/doi.org\/10.1093\/ndt\/gfw338","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"8956_CR5","unstructured":"Overall readmissions and readmissions related to dehydration after creation of an ileostomy: a systematic review and meta-analysis - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/35192122\/. Accessed 20 Mar 2023"},{"key":"8956_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000525029","volume":"147","author":"C Garc\u00eda-Carro","year":"2023","unstructured":"Garc\u00eda-Carro C, Draibe J, Soler MJ (2023) Onconephrology: update in anticancer drug-related nephrotoxicity. Nephron 147:65\u201377. https:\/\/doi.org\/10.1159\/000525029","journal-title":"Nephron"},{"key":"8956_CR7","unstructured":"Nephrotoxicity in cancer treatment: an overview - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/32355641\/. Accessed 6 Sep 2024"},{"key":"8956_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/07853890510007205","volume":"37","author":"NH Lameire","year":"2005","unstructured":"Lameire NH, Flombaum CD, Moreau D, Ronco C (2005) Acute renal failure in cancer patients. Ann Med 37:13\u201325. https:\/\/doi.org\/10.1080\/07853890510007205","journal-title":"Ann Med"},{"key":"8956_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.02780312","volume":"7","author":"MA Perazella","year":"2012","unstructured":"Perazella MA (2012) Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol CJASN 7:1713\u20131721. https:\/\/doi.org\/10.2215\/CJN.02780312","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"8956_CR10","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.ackd.2021.08.001","volume":"28","author":"S Gupta","year":"2021","unstructured":"Gupta S, Portales-Castillo I, Daher A, Kitchlu A (2021) Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis 28:402-414.e1. https:\/\/doi.org\/10.1053\/j.ackd.2021.08.001","journal-title":"Adv Chronic Kidney Dis"},{"key":"8956_CR11","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s10157-016-1327-z","volume":"21","author":"R Ishitsuka","year":"2017","unstructured":"Ishitsuka R, Miyazaki J, Ichioka D et al (2017) Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients. Clin Exp Nephrol 21:732\u2013740. https:\/\/doi.org\/10.1007\/s10157-016-1327-z","journal-title":"Clin Exp Nephrol"},{"key":"8956_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.semnephrol.2010.09.003","volume":"30","author":"V Launay-Vacher","year":"2010","unstructured":"Launay-Vacher V (2010) Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol 30:548\u2013556. https:\/\/doi.org\/10.1016\/j.semnephrol.2010.09.003","journal-title":"Semin Nephrol"},{"key":"8956_CR13","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF et al (2017) A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist 22:609\u2013619. https:\/\/doi.org\/10.1634\/theoncologist.2016-0319","journal-title":"Oncologist"},{"key":"8956_CR14","doi-asserted-by":"publisher","first-page":"239936932211064","DOI":"10.1177\/23993693221106490","volume":"6","author":"M Delaye","year":"2022","unstructured":"Delaye M, Try M, Campedel L et al (2022) Development and organization of onco-nephrology in France, comment on \u201cThe path toward the creation of the American Society of Onco-Nephrology (ASON).\u201d J Onco-Nephrol 6:239936932211064. https:\/\/doi.org\/10.1177\/23993693221106490","journal-title":"J Onco-Nephrol"},{"key":"8956_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.nephro.2021.05.006","volume":"17","author":"V Oli\u00e9","year":"2021","unstructured":"Oli\u00e9 V, Cheddani L, Stengel B et al (2021) Prevalence of chronic kidney disease in France, Esteban study 2014\u20132016. Nephrol Ther 17:526\u2013531. https:\/\/doi.org\/10.1016\/j.nephro.2021.05.006","journal-title":"Nephrol Ther"},{"key":"8956_CR16","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ndt\/gfw382","volume":"32","author":"H Izzedine","year":"2017","unstructured":"Izzedine H, Mateus C, Boutros C et al (2017) Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 32:936\u2013942. https:\/\/doi.org\/10.1093\/ndt\/gfw382","journal-title":"Nephrol Dial Transplant"},{"key":"8956_CR17","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1093\/annonc\/mdv136","volume":"26","author":"V Launay-Vacher","year":"2015","unstructured":"Launay-Vacher V, Aapro M, De Castro G et al (2015) Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26:1677\u20131684. https:\/\/doi.org\/10.1093\/annonc\/mdv136","journal-title":"Ann Oncol"},{"key":"8956_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/23993693221079647","volume":"6","author":"A Rashidi","year":"2022","unstructured":"Rashidi A, Jhaveri KD, Workeneh BT, Gupta S (2022) The path toward the creation of the American Society of Onco-Nephrology (ASON). J Onco-Nephrol 6:3\u20135. https:\/\/doi.org\/10.1177\/23993693221079647","journal-title":"J Onco-Nephrol"},{"key":"8956_CR19","unstructured":"(2021) ASSOGRIFON. https:\/\/assogrifon.webnode.fr\/. Accessed 12 Mar 2023"},{"key":"8956_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1159\/000517695","volume":"199","author":"C Fofi","year":"2021","unstructured":"Fofi C, Festuccia F (2021) Onconephrology: a new challenge for the nephrologist. Contrib Nephrol 199:91\u2013105. https:\/\/doi.org\/10.1159\/000517695","journal-title":"Contrib Nephrol"},{"key":"8956_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/ndt\/gfy188","volume":"33","author":"L Cosmai","year":"2018","unstructured":"Cosmai L, Porta C, Perazella MA et al (2018) Opening an onconephrology clinic: recommendations and basic requirements. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 33:1503\u20131510. https:\/\/doi.org\/10.1093\/ndt\/gfy188","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"8956_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s13187-022-02201-8","author":"M Delaye","year":"2022","unstructured":"Delaye M, Try M, Rousseau A et al (2022) Onco-nephrology: physicians\u2019 expectations about a new subspecialty. J Cancer Educ Off J Am Assoc Cancer Educ. https:\/\/doi.org\/10.1007\/s13187-022-02201-8","journal-title":"J Cancer Educ Off J Am Assoc Cancer Educ"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08956-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-024-08956-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-024-08956-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T09:13:31Z","timestamp":1731489211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-024-08956-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["8956"],"URL":"https:\/\/doi.org\/10.1007\/s00520-024-08956-8","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"31 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Research Ethics Committee of Sorbonne Universit\u00e9 on July 13th, 2021 (CER-2020\u2013109). All participants were informed of the study purpose by an information note, and provided informed oral consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"P Corbaux received travel support from Daiichi-Sankyo\/Astrazeneca and Novartis. C. Isnard-Bagnis served as a consultant, received honorarium and travel reimbursements from Astrazeneca, Baxter and GSK. L. Campedel served as a consultant, received honorarium and travel reimbursements from Pfizer, BMS, MSD, Bayer, Janssen and Ipsen. O. Afchain declares disclosures with IPSEN M. Jamelot declares disclosures with BMS, Astellas, IPSEN. Other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"763"}}